Linezolid

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Antibiotic from the active substance class of oxazolidinones. In addition, the substance is considered a reversible, non-selective MAO inhibitor without antidepressant effect at doses similar to those used in antibiotic therapy.

Spectrum of action
This section has been translated automatically.

  • Bacteriostatically effective against Gram-positive aerobes such as enterococci, staphylococci (incl. MRSA), streptococci and Gram-positive anaerobes such as clostridia and peptostreptococci. Not effective against gram negative pathogens!
  • Notice! Low cross-resistance with other antibiotic classes, also effective against pathogens with resistance to penicillin, oxacillin and vancomycin!

Indication
This section has been translated automatically.

Severe skin or soft tissue infections caused by gram-positive pathogens, nosocomial and ambulantly acquired pneumonia.

Pregnancy/nursing period
This section has been translated automatically.

Insufficient data on use during pregnancy or breastfeeding (in case of therapy: weaning!).

Dosage and method of use
This section has been translated automatically.

Pat. > 18 y.: 2 times/day 600 mg p.o./i.v.

Note ! Regular, weekly blood count checks during therapy!

Undesirable effects
This section has been translated automatically.

Frequent: headache, mycosis (especially vulvovaginal candidiasis), gastrointestinal symptoms with taste disorders, diarrhoea, nausea, vomiting, transient liver dysfunction.

Preparations
This section has been translated automatically.

Zyvoxide

Note(s)
This section has been translated automatically.

  • Fully bioavailable after oral administration
  • Good tissue penetration
  • Liquor flow
  • Good tolerance
  • No cross-resistance to other antibiotics.

Literature
This section has been translated automatically.

  1. Ntziora F et al (2007) Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 41: 296-308

Authors

Last updated on: 29.10.2020